SLC5A2 and diabetes mellitus: CGM use in conjunction with ≥ 1 of five anti‐diabetes medication classes: metformin, sulfonylureas, sodium‐glucose cotransporter‐2 (SGLT2) inhibitors, dipeptidyl peptidase‐4 (DPP‐4) inhibitors and/or glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) was required.